Envista (NYSE:NVST) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of Envista (NYSE:NVST) from a strong-buy rating to a buy rating in a report published on Saturday morning.

A number of other brokerages have also recently issued reports on NVST. Zacks Research cut Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Stifel Nicolaus set a $25.00 price target on shares of Envista in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d)” rating on shares of Envista in a research report on Monday, December 15th. Mizuho set a $19.00 target price on shares of Envista in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. increased their target price on shares of Envista from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Envista presently has a consensus rating of “Hold” and a consensus target price of $21.77.

Envista Stock Up 0.1%

NVST opened at $22.27 on Friday. Envista has a 12 month low of $14.22 and a 12 month high of $22.68. The company has a market cap of $3.66 billion, a PE ratio of 247.47, a price-to-earnings-growth ratio of 1.10 and a beta of 1.02. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 0.47. The company has a 50 day moving average of $20.35 and a 200 day moving average of $20.26.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Envista had a net margin of 0.58% and a return on equity of 5.90%. The business had revenue of $669.90 million for the quarter, compared to analysts’ expectations of $639.49 million. During the same quarter in the previous year, the firm posted $0.12 EPS. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. On average, sell-side analysts expect that Envista will post 1 EPS for the current year.

Hedge Funds Weigh In On Envista

Several institutional investors have recently modified their holdings of the company. Farther Finance Advisors LLC lifted its position in Envista by 317.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after buying an additional 1,026 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in Envista by 16,711.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after acquiring an additional 1,504 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after acquiring an additional 949 shares in the last quarter. SJS Investment Consulting Inc. lifted its holdings in shares of Envista by 10,356.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 2,405 shares of the company’s stock worth $49,000 after acquiring an additional 2,382 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Envista by 378.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock worth $47,000 after acquiring an additional 1,909 shares during the last quarter.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.